分级分组1前列腺癌主动监测:大型前瞻性队列长期结局
该前瞻性队列研究纳入1818例非常低危或低危前列腺癌患者,中位随访5.0年,评估主动监测的长期生存与转移结局。结果显示10年和15年前列腺癌特异性死亡或转移的累积发生率均为0.1%(95%CI 0.04-0.6%),活检分级重分类5年、10年、15年累积发生率分别为21%、30%、32%。
要点
- 分级分组1前列腺癌主动监测下10年和15年癌症死亡或转移风险均<1%。
- 活检分级重分类5年、10年、15年累积发生率分别为21%、30%、32%。
- 入组前接受mpMRI者活检分级重分类风险更低,支持mpMRI用于确认主动监测资格。
核心结论
- 在大型单中心前瞻性主动监测队列中,长期随访癌症死亡或转移风险<1%,支持对多数分级分组1前列腺癌患者采用主动监测。
研究设计与样本
- 前瞻性、开放性入组队列研究,1995年至2018年7月在一家三级学术机构开展,纳入非常低危或低危前列腺癌患者1818例,中位随访5.0年(四分位距2.0-9.0)。
主要发现
- 共发生88例非前列腺癌死亡、4例前列腺癌死亡和1例转移。
- 前列腺癌特异性死亡或转移的10年和15年累积发生率均为0.1%(95%CI 0.04-0.6%)。
- 活检分级重分类的5年、10年、15年累积发生率分别为21%、30%、32%。
- 多变量分析显示活检分级重分类与年龄较大、非裔美国人种族、PSA密度和活检癌症体积增加相关,入组前接受mpMRI者更少发生分级重分类。
临床怎么用
- 数据支持对多数分级分组1前列腺癌患者采用主动监测,但需注意该队列选择与监测强度高于许多当代主动监测项目。
- 入组前mpMRI可作为综合风险评估的一部分,用于确认主动监测资格。
局限性
- 单中心研究,选择与监测方案比许多当代主动监测项目更严格,具体结局可能在监测强度较低的项目中不同。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Active surveillance (AS) is the preferred management option for most men with grade group (GG) 1 prostate cancer (PCa). Questions persist regarding long-term outcomes and the optimal approach to AS. OBJECTIVE: To determine survival and metastatic outcomes in AS patients. Secondary objectives were to measure the cumulative incidence and association of patient-level factors on biopsy grade reclassification. DESIGN, SETTING, AND PARTICIPANTS: A prospective, active, open-enrollment cohort study was conducted from 1995 through July 2018 at a tertiary-care academic institution. Patients with very-low-risk or low-risk PCa were enrolled. INTERVENTION: AS with semiannual prostate-specific antigen (PSA) and digital rectal examination, serial prostate biopsy, and multiparametric magnetic resonance imaging (mpMRI). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The 10- and 15-yr cumulative incidences of primary and secondary outcomes were determined. RESULTS AND LIMITATIONS: Overall, 1818 men were monitored on AS for a median of 5.0yr (interquartile range 2.0-9.0). There were 88 non-PCa deaths, four PCa deaths, and one additional case of metastasis. The cumulative incidence of PCa-specific mortality or metastasis was 0.1% (95% confidence interval, 0.04-0.6%) at both 10 and 15yr. The 5-, 10-, and 15-yr cumulative incidences of biopsy grade reclassification were 21%, 30%, and 32%, respectively. On multivariable analysis, biopsy grade reclassification was associated with older age, African-American race, PSA density, and increased cancer volume on biopsy, and men who underwent mpMRI prior to enrollment were less likely to undergo grade reclassification. Our selection and monitoring are more stringent than many other contemporary AS programs. CONCLUSIONS: In a large, single-institution, prospective AS cohort, the risk of cancer death or metastasis was <1% over long-term follow-up. Consistent with clinical guidelines, these data support the use of AS for the management of most men diagnosed with GG1 PCa. PATIENT SUMMARY: This study investigated long-term outcomes in patients with grade group 1 prostate cancer managed with active surveillance (AS). Ten years after enrolling in AS, the risk of metastasis or death from prostate cancer was <1%, while 48% of men switched to treatment. Patients who underwent multiparametric magnetic resonance imaging (mpMRI)/ultrasound-fusion targeted biopsy prior to enrollment were less likely to experience biopsy grade reclassification during follow-up, suggesting a role for mpMRI as part of a comprehensive risk assessment to confirm AS eligibility. These findings support the safety of AS in most men with grade group 1 prostate cancer, but specific outcomes may differ in programs with less intensive monitoring.
引用
- Tosoian JJ, Mamawala M, Epstein JI, et al. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort. Eur Urol. 2020. PMID: 31918957. doi:10.1016/j.eururo.2019.12.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。